Avalyn Pharma Inc. (NASDAQ:AVLN) Sees Large Increase in Short Interest

Posted by on Jun 3rd, 2026

Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 562,374 shares, an increase of ∞ from the April 30th total of 0 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 416,629 shares, the short-interest ratio is presently 1.3 days.

Analyst Ratings Changes

Several analysts have recently commented on AVLN shares. Morgan Stanley started coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price for the company. Zacks Research raised Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group began coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 price objective for the company. Finally, Evercore began coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $59.00.

Read Our Latest Stock Report on Avalyn Pharma

Insider Buying and Selling at Avalyn Pharma

In other Avalyn Pharma news, Director Jill Carroll bought 277,778 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the transaction, the director directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 14.55% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Avalyn Pharma Price Performance

AVLN opened at $25.72 on Wednesday. Avalyn Pharma has a 1 year low of $25.05 and a 1 year high of $32.22.

Avalyn Pharma Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

Featured Stories

Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.